Cargando…

Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas

BACKGROUND: Programmed cell death ligand-1 (PD-L1) expression has been reported in up to 61% of high grade gliomas (HGG). The purpose of this study was to describe safety and efficacy of PD-1 inhibition in patients with refractory HGGs. METHODS: This Institutional Review Board approved single center...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reiss, Samantha N., Yerram, Prakirthi, Modelevsky, Lisa, Grommes, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735528/ https://www.ncbi.nlm.nih.gov/pubmed/29254497 http://dx.doi.org/10.1186/s40425-017-0302-x

Ejemplares similares

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
por: Yerram, Prakirthi, et al.
Publicado: (2023)

Multifocal high-grade glioma radiotherapy safety and efficacy
por: Fleischmann, Daniel Felix, et al.
Publicado: (2021)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

A systematic approach towards missing lab data in electronic health records: A case study in non‐small cell lung cancer and multiple myeloma
por: Sondhi, Arjun, et al.
Publicado: (2023)

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
por: Lin, Long-Wang, et al.
Publicado: (2023)

Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews
por: Ou, Shun-Long, et al.
Publicado: (2022)

Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study
por: Zhang, Weijie, et al.
Publicado: (2022)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
por: Liao, Pei-Fei, et al.
Publicado: (2023)

Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
por: Bouffet, Eric, et al.
Publicado: (2023)

Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
por: Xu, Weilin, et al.
Publicado: (2017)

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3
por: Eichkorn, Tanja, et al.
Publicado: (2023)

Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma
por: Hölzl, Dorothee, et al.
Publicado: (2021)

Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity
por: Treiber, Hannes, et al.
Publicado: (2022)

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature
por: Jeck, Jennifer, et al.
Publicado: (2018)

Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational Study
por: Barbaro, Marissa, et al.
Publicado: (2022)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis
por: Pattanaik, Smita, et al.
Publicado: (2019)

Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis
por: Xu, Yanan, et al.
Publicado: (2023)

Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma
por: Lei, Jin, et al.
Publicado: (2023)

Phase I Study of a Combination of Fluvastatin and Celecoxib in Children with Relapsing/Refractory Low-Grade or High-Grade Glioma (FLUVABREX)
por: Leblond, Pierre, et al.
Publicado: (2023)

Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience
por: Guan, Yun, et al.
Publicado: (2021)

Long‐term efficacy and safety of programmed death‐1 (PD‐1) antibody alone in relapsed/refractory human immunodeficiency virus‐associated Hodgkin lymphoma
por: Wang, Chaoyu, et al.
Publicado: (2022)

EPCT-11. PHASE 1 STUDY OF FLUVASTATIN-CELECOXIB COMBINATION IN CHILDREN WITH RELAPSING/REFRACTORY OPTICO-CHIASMATIC LOW-GRADE GLIOMA OR HIGH-GRADE GLIOMAS (FLUVABREX): FINAL RESULTS
por: Andrew, Nicolas, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review
por: Lazarus, Gilbert, et al.
Publicado: (2019)

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
por: Decraene, Brecht, et al.
Publicado: (2022)

A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: Safety, efficacy, visual morbidity, and outcomes
por: Green, Katherine, et al.
Publicado: (2022)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study
por: Li, Shenglong, et al.
Publicado: (2023)

Effect of prognostic classification on temsirolimus efficacy and safety in patients with relapsed or refractory mantle cell lymphoma: a retrospective analysis
por: Hess, Georg, et al.
Publicado: (2015)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: A meta-analysis
por: Zhao, Heng-Nan, et al.
Publicado: (2021)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
por: Sun, Feifei, et al.
Publicado: (2020)

Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study
por: Teixidor, Pilar, et al.
Publicado: (2016)

Unlocking the power of precision medicine for pediatric low-grade gliomas: molecular characterization for targeted therapies with enhanced safety and efficacy
por: Cipri, Selene, et al.
Publicado: (2023)

Lower Grade Gliomas
por: Youssef, Gilbert, et al.
Publicado: (2020)

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis
por: Liu, Yi, et al.
Publicado: (2019)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_32sa589u564h8pt4j0krc48m43